Ketamine and Magnesium in Erector Spinae Plane Block

Cukurova University60 enrolled

Overview

In this study, it will aimed to evaluate the effect of magnesium sulfate and ketamine HCl added to local anesthetic on postoperative pain management in the ultrasound-guided erector spina plane (ESP) block in patients will undergo video-assisted thoracoscopic surgery.

Patients who will undergo lung resection with elective video-assisted thoracoscopic surgery will be included in the study. After routine monitoring, general anesthesia induction, and intubation with a double-lumen tube, patients who are placed in a lateral position will receive an ESP block at the T5 level, accompanied by ultrasonography, for postoperative analgesia. For this purpose; Group I (control group) 0.5% bupivacaine 20 ml, Group II 0.5% bupivacaine 20 ml+150 mg MgSO4, Group III 0% ,5 bupivacaine 20 ml+2 mg/kg ketamine HCl will be administered. In all groups, the total volume will completed to 25 ml with 0.9% NaCl. After surgery, hemodynamic values (heart rate, systolic and diastolic blood pressure), oxygen saturation, VAS scores (at rest and effort), Ramsey sedation score, patients satisfaction scores, PCA morphine consumption, additional analgesic requirements, and side effects will be recorded.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Postoperative Analgesia

Interventions

BupivacainDRUG

Bupivacaine is a local anesthetic agent commonly used in ESP block.

Magnesium sulfateDRUG

Magnesium is an adjuvant agent that can be added to the local anesthetic agent to increase analgesic effectiveness..

Ketamine HydrochlorideDRUG

Ketamine Hydrochloride is an also adjuvant agent that can be added to the local anesthetic to increase analgesic effectiveness.

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * lung resection with video-assisted thoracoscopy, * voluntarily agree to participate in the study, * over 18 years old, * ASA I-III Exclusion Criteria: * ASA\>III * Coagulation disorders or anticoagulant agent therapy, * Allergy or hypersensitivity to any drug to be will be used in the study, * Epilepsy, * High intracranial pressure, * Unwillingness to participate in the study * Inability to use the PCA device

Locations (1)

Cukurova University

Adana, Adana, Turkey (Türkiye)

Outcomes

Primary Outcomes

pain scores

postoperative pain scores will recorded used Visual Analog Scale (VAS, 0= no pain, 10=worst pain)

Time frame: Change from baseline pain scores at 24 hours

morphine consumption

At the end of the surgery, patients will allowed to use the patient controlled analgesia (PCA) device. The PCA will deliver bolus doses of morphine (0,02 mg/kg) every 10 minutes without a background infusion.

Time frame: Change from baseline morphine consumption at 24 hours

Secondary Outcomes

side effects

All of patients will visited in the thoracic surgery ward after surgery and side effects (if occured) will recorded.

Time frame: postoperative 24 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.